Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE

The board of directors (the "**Board**") of Sihuan Pharmaceutical Holdings Group Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") announces that:

Ms. Chen Yanling ("**Ms. Chen**"), an existing executive director of the Company, will be appointed as a member of the nomination committee of the Company (the "**Nomination Committee**") with effect from 1 September 2025.

The biographical details of Ms. Chen were set out in the annual report 2024 of the Company published on 28 April 2025. As at the date of this announcement, such information remains unchanged.

Immediately following the above appointment of Ms. Chen, the Nomination Committee will continue to consist of a majority of independent non-executive directors, including at least one director of different gender. Among them, three are independent non-executive directors (being Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan) and two are executive directors (being Dr. Guo Weicheng and Ms. Chen). The Board believes that such change in appointment will enhance the effectiveness and diversity of the Board and further improve the overall corporate governance practices of the Company.

The Board would like to welcome Ms. Chen to her new position on the Nomination Committee.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 29 August 2025

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.